NCT05069298 is a NA clinical trial of Silibinin A in Overweight and Obesity, sponsored by Universidad Católica San Antonio de Murcia.

Who is sponsoring NCT05069298?

NCT05069298 is sponsored by Universidad Católica San Antonio de Murcia.

What drugs are being tested in NCT05069298?

Interventions in NCT05069298: Silibinin A.

What condition does NCT05069298 study?

NCT05069298 studies Overweight and Obesity, Hypercholesterolemia, Hypertriglyceridemia.

Is NCT05069298 still recruiting?

NCT05069298 is currently status unknown. Last updated 23 June 2023.

Last reviewed 2023-06-23 · How we verify

NCT05069298

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Silibinin(A) as a Potential Anti-obesity Agent

Status unknown NA Last updated 23 June 2023

What this trial tests

NA trial testing Silibinin A in Overweight and Obesity in 60 participants. Status unknown.

Timeline

12 January 2023

Primary endpoint
1 December 2023

21 December 2023

Quick facts

Lead sponsor	Universidad Católica San Antonio de Murcia
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	12 January 2023
Primary completion	1 December 2023
Estimated completion	21 December 2023
Sites	1 location across Spain

Drugs / interventions tested

Silibinin A

Conditions studied

Overweight and Obesity — all drugs for Overweight and Obesity →
Hypercholesterolemia — all drugs for Hypercholesterolemia →
Hypertriglyceridemia — all drugs for Hypertriglyceridemia →

Sponsor

Universidad Católica San Antonio de Murcia

Who can join

Adults 18 to 60, any sex, with Overweight and Obesity or Hypercholesterolemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our preliminary reports have found in silico and in vitro that the milk thistle derivative Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical anti-obesity drug orlistat. Therefore, the investigators want to carry out the present trial in order to confirm that Silibinin(A) is able to in vivo inhibit pancreatic lipase, which will reduce the fat absorption and therefore will decrease the amount of energy from food intake. Considering that milk thistle has been extensively studied in humans as liver-protector, the investigators consider that the use of human subjects will be of great interest to accelerate the employment of this compound to improve the effectiveness of dietary treatment in overweight/obese subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds.
Amiri M, Molavi O, Sabetkam S, Jafari S, et al · · 2023 · cited 43× · PMID 37705051 · DOI 10.1186/s12935-023-03058-7
Effect of Silibinin on Human Pancreatic Lipase Inhibition and Gut Microbiota in Healthy Volunteers: A Randomized Controlled Trial.
Ponce Martínez C, Murcia García E, Pérez Sánchez H, Milagro FI, et al · · 2024 · cited 3× · PMID 39684564 · DOI 10.3390/ijms252312853

Verify or expand the search:

Other recruiting trials for Overweight and Obesity

Currently open trials in the same condition.

NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting

Other Universidad Católica San Antonio de Murcia trials

Trials by the same sponsor.

NCT07397910 — Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection · NA · not yet recruiting
NCT07519980 — Xanthigen and Its Impact on Weight and Metabolic Health · NA · recruiting
NCT07391189 — Healthy Effects of Adapted Aikido in People With Grip Disfunction · NA · recruiting
NCT07379931 — Evaluating a Liquid Extract of Carob to Improve Blood Sugar in People With Prediabetes · NA · not yet recruiting
NCT07488000 — Plyometric Exercises During the Winter Pre-season in Sprinters · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05069298 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Católica San Antonio de Murcia
Last refreshed: 23 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05069298.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing